APLMW (Apollomics) Research & Development: $5.53 Mil (TTM As of Dec. 2025)


APLMW Apollomics Inc APLMW
31 GF Score
Price $0.01
! 5 Warning Signs
View Full Analysis

What is Apollomics Research & Development?

Apollomics APLMW -7.91% 31 Research & Development is $5.53 Mil as of Dec. 2025. GuruFocus rates APLMW with a GF Score™ of 31/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Apollomics's Research & Development for the six months ended in Dec. 2025 was $0.91 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $5.53 Mil.

Apollomics  (NAS:APLMW) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Apollomics Research & Development Related Terms

Apollomics Research & Development Historical Data

* Premium members only.

The historical data trend for Apollomics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics Research & Development Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 35.57 35.46 34.19 24.57 5.53

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 17.68 16.93 7.64 4.62 0.91
APLMW
31GF Score
Apollomics Inc APLMW
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollomics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $5.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $5.53 Mil mean?
Apollomics (APLMW) has a Research & Development of $5.53 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Apollomics and its competitors.
Is Apollomics' Research & Development too high?
Apollomics' current Research & Development is $5.53 Mil. Overall, Apollomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Research & Development compare to TVRD and PLRZ?
Apollomics' Research & Development of $5.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Apollomics and its competitors. Apollomics's current Research & Development is $5.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLMW) has a current Research & Development of $5.53 Mil. The current Research & Development is $5.53 Mil. Apollomics' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Apollomics (APLMW), the current Research & Development is $5.53 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apollomics Business Description

Other Exchanges APLM:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score

Get the complete analysis for APLMW

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price